What is iTeos Therapeutics, Inc. (ITOS)?

iTeos Therapeutics, Inc. (ITOS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ITOS?

The current price of ITOS is $10.15. Prices are updated in real time on Stocks360.

What is ITOS's price-to-earnings (PE) ratio?

ITOS's trailing twelve-month PE ratio is -3.06, based on current price and earnings per share data available on Stocks360.

What is ITOS's market capitalization?

ITOS's market capitalization is $448,684,810.00, placing it in the small-cap tier.

iTeos Therapeutics, Inc. (ITOS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$10.15

Market Cap

$448.68M

PE (TTM)

-3.06

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.49

Day Range

$10.15 – $10.15

52-wk Range

$4.80 – $17.63

Avg Volume

N/A

Volume

11.01M

iTeos Therapeutics, Inc. (ITOS) is a publicly traded company in the Healthcare sector. Latest price: $10.15. Market cap $448.68M. Trailing PE -3.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 6, 2025

EPS $-1.51 vs est. $-1.12

Missed by $0.39

Proprietary Signals

Signal snapshot temporarily unavailable.

About iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.06×
P/S (TTM)	12.82×
P/B	0.70×
PEG	0.06×
P/FCF (TTM)	-4.50×
EV / EBITDA	-2.56×
EV / Sales	8.90×
Earnings Yield	-32.72%
Free Cash Flow Yield	-22.25%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$311.65M
Revenue (TTM)	$35.00M
Net Income (TTM)	-$146.80M
Free Cash Flow (TTM)	-$99.81M
Net Debt	-$137.03M
Working Capital	$469.18M
Gross Margin	96.46%
Operating Margin	-455.79%
Net Margin	-384.04%
Return on Equity	-23.07%
Return on Invested Capital	-24.62%